Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Head & Neck 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 97Lung Neoplasms 35Colorectal Neoplasms 35Pancreatic Neoplasms 13Adenocarcinoma of Lung 10Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Colonic Neoplasms 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6Breast Neoplasms 6Rectal Neoplasms 5Melanoma 5Endometrial Neoplasms 5Stomach Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Triple Negative Breast Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Recurrence 2Pleural Effusion, Malignant 2Esthesioneuroblastoma, Olfactory 2Carcinoma, Pancreatic Ductal 2

Interventions

sotorasib 1pembrolizumab 1lorlatinib 1liposomal doxorubicin 1encorafenib 1cemiplimab 1binimetinib 1berzosertib 1Topotecan 1Taxes 1Paclitaxel 1PX-866 1NVP-BKM120 1Lomustine 1Irinotecan 1Gemcitabine 1Everolimus 1Doxorubicin 1Docetaxel 1Cetuximab 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Cetuximab × Thoracic × Clear all
NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
53 enrolled
CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡